| | CXCL13 | CCL19 |
|---|
Treatment | LT | MO | NT | LT | MO | NT |
|---|
Age in weeks | | | | Acini/duct | Infiltrate | Acini/duct | Infiltrate | Acini/duct | Infiltrate |
|---|
9 | - | - | 0/4 | - | - | - | - | 4/4 | 0/4 |
12 | 2/4 | 1/4 | 4/4 | 4/4 | 0/4 | 4/4 | 1/4 | 4/4 | 2/4 |
16 | 4/4 | 4/4 | 4/4 | 4/4 | 0/4 | 4/4 | 4/4 | 4/4 | 3/4 |
19 | 2/4 | 4/4 | 3/3 | 3/4 | 0/4 | 2/4 | 2/4 | 2/3 | 1/3 |
- Treatment with either lymphotoxin-beta receptor-immunoglobulin fusion protein (LTβR-Ig) or mouse monoclonal IgG1 (MOPC 21) was started at week 9. Euthanization was carried out 1 week after the last injection. Mice receiving either LTβR-Ig or MOPC 21 and euthanized at 12 weeks of age had received 3 injections, those euthanized at 16 weeks of age had received 7 injections, and those euthanized at 19 weeks of age had received 10 injections. -, no mice in these groups; LT, mice treated with lymphotoxin-beta receptor-immunoglobulin fusion protein; MO, mice treated with mouse monoclonal IgG1; NT, mice not treated.
